Abstract:Introduction Everolimus and sirolimus are immunosuppressants that inhibit mechanistic target of rapamycin (mTOR) used to prevent graft rejection after heart transplantation. Hypersensitivity pneumonitis is a known class effect toxicity of mTOR inhibitors. Prognosis is favorable if medication is stopped before there is extensive damage. We report two cases of hypersensitivity pneumonitis in patients receiving mTOR inhibitors. Case 1 A 45-year-old female who was 7 years S/P heart transplant for NICM presented to clinic for progressive shortness of breath for one month. Her post-transplant course was complicated by antibody-mediated rejection and allograft vasculopathy, for which mycophenolate mofetil (MMF) was substituted for everolimus 3months prior to her presentation. CT scan showed new ground glass opacities (GGO) throughout the right lung and the left lower lobe (figure 1a). An extensive infectious workup was negative. Bronchoscopy with BAL resulted in elevated polymorphonuclear leukocytes (55%), lymphocytes (4%), and macrophages (41%) with negative cultures and antigen testing. She remained hemodynamically stable on room air and was discharged on MMF instead of everolimus. After 2 months, her symptoms had improved, and repeat CT scan showed near complete resolution of prior infiltrates (Figure 1b). Case 2 A 41-year-old female who was 9 years S/P heart transplant for peripartum cardiomyopathy presented with 6 months of progressive shortness of breath and productive cough. MMF was switched to sirolimus for de novo donor-specific antibodies 6 months prior. On presentation, she was hemodynamically stable on room air. Labs were significant for WBC 20 x109/L with 48% eosinophils. CT scan showed patchy diffuse GGO (figure 2a). An extensive infectious workup was negative. Bronchoscopy with BAL showed 93% Eosinophils. The diagnosis of mTOR-induced eosinophilic pneumonitis was made, and sirolimus was stopped. She was discharged on a higher dose of MMF. Her symptoms continued to improve. Four months later, she had a repeat CT scan which showed resolution of GGO (figure 2b). Conclusion We present two cases of reversible mTOR inhibitor-induced hypersensitivity pneumonitis with full clinical and radiographic recovery with discontinuation of therapy. It is vital to screen for symptoms and recognize the diagnosis early as discontinuation of therapy can prevent significant morbidity. .

Sirolimus-induced pulmonary toxicity without recurrence more than 8 years after everolimus replacement in a renal transplant patient with recurrent skin SCC: a case report

Everolimus And Sirolimus Hypersensitivity Pneumonitis With Full Recovery: A Case Series

Inhibitors of mTOR and risks of allograft failure and mortality in kidney transplantation.

Life-Threatening Everolimus-Associated Pneumonitis: A Case Report and a Review of the Literature

Everolimus-Induced Systemic Serositis After Simultaneous Liver and Kidney Transplantation: A Case Report

mTOR inhibitors after lung transplantation: a real-life experience

Clinicopathological Characteristics of Everolimus-Associated Interstitial Lung Disease: A Single-Center Consecutive Analysis

Effect of mammalian-target-of-rapamycin inhibitors on the cancer risk in patients receiving calcineurin inhibitors: Data mining of a spontaneous reporting database

Conversion from cyclosporine to sirolimus in chronic renal allograft dysfunction: a 4-year prospective study.

A comprehensive review of everolimus clinical reports: a new mammalian target of rapamycin inhibitor

Conversion from Calcineurin Inhibitors to Sirolimus in Chronic Allograft Nephropathy: a 4-Year Prospective Study

Wound Healing Complications and the Use of Mammalian Target of Rapamycin Inhibitors in Kidney Transplantation

Use of sirolimus in solid organ transplantation

Everolimus and Sirolimus in Transplantation-Related but Different.

Pneumocystis Jirovecii Pneumonia During Sirolimus Therapy for Kaposiform Hemangioendothelioma

Wound healing complications and the use of mammalian target of rapamycin inhibitors in kidney transplantation: a critical review of the literature.

Use of sirolimus as an adjuvant therapy for kidney transplant recipients with high-risk cutaneous squamous cell carcinomas: a prospective non-randomized controlled study

The Role of Mammalian Target of Rapamycin Inhibitors in the Management of Post‐transplant Malignancy

Long-term safety and influence on growth in patients receiving sirolimus: a pooled analysis

Pharmacokinetic Factors and Therapeutic Drug Monitoring of Sirolimus

A New Hypothesis Describing the Pathogenesis of Oral Mucosal Injury Associated with the Mammalian Target of Rapamycin (mTOR) Inhibitors